Germany – Pharmaceutical products – Conclusion of a non-exclusive discount agreement in accordance with Section 130a Paragraph 8 SGB V for the active ingredient Interferon beta-1a (exclusively for subcutaneous use), ATC L03AB07 f. d.Z. 01.11.26-31.10.28
By: DAK health📍 GermanyOpen
Key Information
| Reference | GB-644964-2026 |
|---|
| Deadline | Sep 5, 2029 12:00 AM |
|---|
| Estimated Value | €1.00 |
|---|
| Category | Advertising & Media |
|---|
| Competition Type | ICB |
|---|
| Funding Source | Self-Funded |
|---|
| Country | Germany |
|---|
| Address | Nagelsweg 27- 31, Hamburg, 20097, Germany |
|---|
| Published | Sep 18, 2026 |
|---|
Description
2.Procedure2.1.procedureTitle: Conclusion of a non-exclusive discount agreement in accordance with Section 130a Paragraph 8 SGB V for the active ingredient interferon beta-1a (exclusively for subcutan...
Full details are available after unlocking this tender.